{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:45:03Z","timestamp":1787262303371,"version":"build-2736575974"},"reference-count":117,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Colorectal cancer is characterized by high incidence worldwide. Despite increased awareness and early diagnosis thanks to screening programmes, mortality remains high, particularly for patients with metastatic involvement. Immune checkpoint inhibitors or poly (ADP-ribose) polymerase (PARP)-inhibitors have met with disappointing results when used in this setting, opposed to other malignancies. New drugs with different mechanisms of action are needed in this disease. Drug repurposing might offer new therapeutic options, as patients with metastatic colorectal cancer often share risk factors for other chronic diseases and thus frequently are on incidental therapy with these drugs. The aim of this review is to summarise the published results of the activity of drugs used to treat chronic medications in patients affected by colorectal cancer. We focused on antihypertensive drugs, Non-Steroid Anti-inflammatory Drugs (NSAIDs), metformin, antidepressants, statins and antibacterial antibiotics. Our review shows that there are promising results with beta blockers, statins and metformin, whereas data concerning antidepressants and antibacterial antibiotics seem to show a potentially harmful effect. It is hoped that further prospective trials that take into account the role of these drugs as anticancer medications are conducted.<\/jats:p>","DOI":"10.3390\/cancers12102724","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T02:56:43Z","timestamp":1600916203000},"page":"2724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing"],"prefix":"10.3390","volume":"12","author":[{"given":"Riccardo","family":"Giampieri","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Giglio","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bittoni","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lanese","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Crocetti","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Copparoni","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Meletani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Lenci","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Lupi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuditta","family":"Baleani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital\u2014Marche Polytechnic University, Ancona, 60126 Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ctrv.2014.06.004","article-title":"The \u201cangiogenetic ladder\u201d, step-wise angiogenesis inhibition in metastatic colorectal cancer","volume":"40","author":"Giampieri","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.critrevonc.2013.05.008","article-title":"Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation","volume":"88","author":"Giampieri","year":"2013","journal-title":"Crit. Rev. Oncol."},{"key":"ref_3","first-page":"CD002745","article-title":"Amantadine and rimantadine for influenza A in children and the elderly","volume":"2014","author":"Santos","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57316","DOI":"10.18632\/oncotarget.17622","article-title":"An updated meta-analysis of amantadine for treating dyskinesia in Parkinson\u2019s disease","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0149-2918(03)80085-1","article-title":"Thalidomide: A review of approved and investigational uses","volume":"25","author":"Matthews","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45703","DOI":"10.1038\/srep45703","article-title":"Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis","volume":"7","author":"Giampieri","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"(2011). Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens., 29, 623\u2013635.","DOI":"10.1097\/HJH.0b013e328344a7de"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/EDE.0000000000001065","article-title":"Renin\u2013Angiotensin\u2013Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer among Medicare Beneficiaries","volume":"30","author":"Htoo","year":"2019","journal-title":"Epidemiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","article-title":"Cancer risk and mortality in users of calcium channel blockers","volume":"89","author":"Thulstrup","year":"2000","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer","volume":"17","author":"Assimes","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/aje\/kwz106","article-title":"Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer","volume":"188","author":"Cui","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.28546","article-title":"Stage-specific associations between beta blocker use and prognosis after colorectal cancer","volume":"120","author":"Jansen","year":"2014","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijc.30717","article-title":"Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study","volume":"141","author":"Jansen","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1097\/MD.0000000000000719","article-title":"Prognostic Value for Incidental Antihypertensive Therapy With \u03b2-Blockers in Metastatic Colorectal Cancer","volume":"94","author":"Giampieri","year":"2015","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fiala, O., Ostasov, P., Sorejs, O., Liska, V., Buchler, T., Poprach, A., and Finek, J. (2019). Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers, 11.","DOI":"10.3390\/cancers11121856"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cardwell, C.R., McMenamin, \u00da., Hicks, B.M., Hughes, C., Cantwell, M.M., and Murray, L.J. (2014). Drugs affecting the renin-angiotensin system and survival from cancer: A population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-28"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.3892\/or.2015.3874","article-title":"Antiproliferative effects of \u03b2-blockers on human colorectal cancer cells","volume":"33","author":"Coelho","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.3389\/fimmu.2019.03082","article-title":"Systemic \u03b2-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of V\u03b39V\u03b42 T-Cells","volume":"10","author":"Baker","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1080\/21691401.2019.1626402","article-title":"Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer","volume":"47","author":"Zhang","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/bjs.10988","article-title":"Effect of beta-blocker therapy on early mortality after emergency colonic cancer surgery","volume":"106","author":"Ahl","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2174\/138920012803341384","article-title":"Aspirin as a chemoprevention agent for colorectal cancer","volume":"13","author":"Lee","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"ref_25","first-page":"421","article-title":"Recent notions on intestinal cancerogenesis, their implications in genetic risk screening and preventive action of non-steroid anti-inflammatory agents","volume":"186","author":"Couturier","year":"2002","journal-title":"Bull. Acad. Natl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bulcan.2017.09.013","article-title":"Aspirine et cancer colorectal","volume":"105","author":"Grancher","year":"2018","journal-title":"Bull. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0006-3495(02)75212-0","article-title":"Fluid Shear Regulates the Kinetics and Molecular Mechanisms of Activation-Dependent Platelet Binding to Colon Carcinoma Cells","volume":"83","author":"Mccarty","year":"2002","journal-title":"Biophys. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2015.07.001","article-title":"The prothrombotic activity of cancer cells in the circulation","volume":"30","author":"Mitrugno","year":"2015","journal-title":"Blood Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"C80","DOI":"10.1152\/ajpcell.00294.2013","article-title":"Physical Biology in Cancer. The physical biology of circulating tumor cells","volume":"306","author":"Phillips","year":"2014","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejim.2016.06.004","article-title":"Aspirin, platelets, and cancer: The point of view of the internist","volume":"34","author":"Santilli","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s13277-015-3959-0","article-title":"Aspirin and salicylic acid decrease c-Myc expression in cancer cells: A potential role in chemoprevention","volume":"37","author":"Ai","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/ph5121346","article-title":"Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent","volume":"5","author":"Dovizio","year":"2012","journal-title":"Pharmaceuticals"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","first-page":"1969","article-title":"Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene","volume":"5","author":"Erisman","year":"1985","journal-title":"Mol. Cell. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/0008-5472.CAN-07-0426","article-title":"Myc Goes Global: New Tricks for an Old Oncogene","volume":"67","author":"Knoepfler","year":"2007","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-Derived Transforming Growth Factor- Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000323936","article-title":"Modulation of Natural Killer Cell Anti-Tumor Reactivity by Platelets","volume":"3","author":"Placke","year":"2011","journal-title":"J. Innate Immun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","article-title":"Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC","volume":"312","author":"Mitrugno","year":"2017","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canep.2018.11.002","article-title":"Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: A systematic review and meta-analysis","volume":"58","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e22433","DOI":"10.1002\/jbt.22433","article-title":"Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells","volume":"34","author":"Seetha","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1073\/pnas.61.1.46","article-title":"Antimetastatic effects associated with platelet reduction","volume":"61","author":"Gasic","year":"1968","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.18632\/aging.102644","article-title":"Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-\u03baB to the COX-2 promoter","volume":"12","author":"Jiang","year":"2020","journal-title":"Aging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clcc.2016.07.011","article-title":"The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients with Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy","volume":"16","author":"Giampieri","year":"2017","journal-title":"Clin. Color. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/bjc.2015.336","article-title":"Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer","volume":"113","author":"Restivo","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Petrelli, F., Ghidini, M., Ghidini, A., Perego, G., Cabiddu, M., Khakoo, S., Oggionni, E., Abeni, C., Hahne, J.C., and Tomasello, G. (2019). Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cancers, 11.","DOI":"10.3390\/cancers11081174"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sobhani, I., Tap, J., Roudot-Thoraval, F., Roperch, J.P., Letulle, S., Langella, P., Corthier, G., Van Nhieu, J.T., and Furet, J.P. (2011). Microbial Dysbiosis in Colorectal Cancer (CRC) Patients. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016393"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/PPO.0000000000000050","article-title":"Gut Microbiome and Colorectal Adenomas","volume":"20","author":"Dulal","year":"2014","journal-title":"Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/cam4.1460","article-title":"Antibiotic-mediated bacteriome depletion in ApcMin\/+ mice is associated with reduction in mucus-producing goblet cells and increased colorectal cancer progression","volume":"7","author":"Kaur","year":"2018","journal-title":"Cancer Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ebiom.2019.09.021","article-title":"Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin\/+ mice","volume":"48","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ismej.2011.109","article-title":"Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers","volume":"6","author":"Wang","year":"2011","journal-title":"ISME J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2016.04.003","article-title":"Antibiotic-Induced Changes in the Intestinal Microbiota and Disease","volume":"22","author":"Becattini","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.it.2012.05.003","article-title":"Antibiotics, microbiota, and immune defense","volume":"33","author":"Ubeda","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10620-015-3828-0","article-title":"Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case-Control Study","volume":"61","author":"Dik","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1136\/gutjnl-2019-318593","article-title":"Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989\u20132012: A matched case\u2013control study","volume":"68","author":"Zhang","year":"2019","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopha.2018.08.165","article-title":"The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer","volume":"108","author":"Yuan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s12094-020-02301-1","article-title":"Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials","volume":"22","author":"Ghosh","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116680","DOI":"10.1016\/j.lfs.2019.116680","article-title":"The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?","volume":"233","author":"Hekmatshoar","year":"2019","journal-title":"Life Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2006.04.053","article-title":"Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells","volume":"541","author":"Arimochi","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000111144","article-title":"Desipramine Induces Apoptotic Cell Death through Nonmitochondrial and Mitochondrial Pathways in Different Types of Human Colon Carcinoma Cells","volume":"81","author":"Arimochi","year":"2007","journal-title":"Pharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s12276-020-0389-x","article-title":"New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells","volume":"52","author":"Rodrigues","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_61","first-page":"277","article-title":"Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice","volume":"33","author":"Zolokov","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/jcmm.14011","article-title":"Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB","volume":"23","author":"Jang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kannen, V., Hintzsche, H., Zanette, D.L., Silva, W.A., Garcia, S.B., Waaga-Gasser, A.M., and Stopper, H. (2012). Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic Carcinogen Mouse Model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050043"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4251\/wjgo.v6.i1.11","article-title":"Antidepressant fluoxetine and its potential against colon tumors","volume":"6","author":"Stopper","year":"2014","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.cellsig.2015.05.008","article-title":"Oncostatic effects of fluoxetine in experimental colon cancer models","volume":"27","author":"Kannen","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"172441","DOI":"10.1016\/j.ejphar.2019.172441","article-title":"Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells","volume":"857","author":"Marcinkute","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e975080","DOI":"10.4161\/23723556.2014.975080","article-title":"Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer","volume":"2","author":"Iskar","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Fang, C.-K., Chen, H.-W., Chiang, I.-T., Chen, C.-C., Liao, J.-F., Su, T.-P., Tung, C.-Y., Uchitomi, Y., and Hwang, J.-J. (2012). Mirtazapine Inhibits Tumor Growth via Immune Response and Serotonergic System. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038886"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(06)70622-2","article-title":"Use of antidepressants and risk of colorectal cancer: A nested case-control study","volume":"7","author":"Xu","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/pds.1808","article-title":"Antidepressant use and colorectal cancer risk","volume":"18","author":"Coogan","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ijc.25322","article-title":"Colorectal cancer risk in relation to antidepressant medication use","volume":"128","author":"Chubak","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bjc.6605996","article-title":"Tricyclic antidepressants and the incidence of certain cancers: A study using the GPRD","volume":"104","author":"Walker","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s10552-012-0073-0","article-title":"Survival of glioma and colorectal cancer patients using tricyclic antidepressants post-diagnosis","volume":"23","author":"Walker","year":"2012","journal-title":"Cancer Causes Control."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/sj.bjc.6605911","article-title":"Antidepressants and Colorectal Cancer: A Population-Based Nested Case-Control Study","volume":"104","author":"Lee","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_75","first-page":"188","article-title":"Antidepressant use and colorectal cancer risk: A Danish population-based case\u2013control study","volume":"104","author":"Riis","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.24537","article-title":"Incidence of cancer and antidepressant medication: Record linkage study","volume":"126","author":"Haukka","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.euroneuro.2015.04.010","article-title":"Anti-depressant therapy and cancer risk: A nested case-control study","volume":"25","author":"Boursi","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1055-9965.EPI-17-1035","article-title":"Antidepressant Use and Risk of Colorectal Cancer in the Women\u2019s Health Initiative","volume":"27","author":"Sturgeon","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/pon.5015","article-title":"Use of antidepressants after colon cancer diagnosis and risk of recurrence","volume":"28","author":"Pocobelli","year":"2019","journal-title":"Psycho-Oncology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/CS20090399","article-title":"Insulin resistance and hyperinsulinaemia in the development and progression of cancer","volume":"118","author":"Godsland","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1940-6207.CAPR-18-0262","article-title":"A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index","volume":"13","author":"Zell","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.tranon.2019.10.011","article-title":"Metofrmin Treatment for diabetes mellitus correlates with progression and survival in colorectal carcinoma","volume":"13","author":"Powell","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_86","first-page":"1","article-title":"Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer","volume":"4","author":"AbdelKhaleq","year":"2018","journal-title":"J. Glob. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/bjc.2012.71","article-title":"Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer","volume":"106","author":"Garrett","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"26448","DOI":"10.18632\/oncotarget.14688","article-title":"Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/gut.2009.190900","article-title":"Effect of statin therapy on colorectal cancer","volume":"59","author":"Bardou","year":"2010","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer","volume":"64","author":"Gazzerro","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ajps.2018.06.004","article-title":"Small GTPases: Structure, biological function and its interaction with nanoparticles","volume":"14","author":"Song","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"re4","DOI":"10.1126\/scisignal.2005970","article-title":"T lymphocyte regulation by mevalonate metabolism","volume":"8","author":"Thurnher","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3389\/fendo.2018.00807","article-title":"Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment","volume":"9","author":"Chimento","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2018.08.070","article-title":"The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery","volume":"175","author":"Xia","year":"2018","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1472-6483(10)60390-2","article-title":"Comparative evaluation of the effects of statins on human stem and cancer cells in vitro","volume":"15","author":"Gauthaman","year":"2007","journal-title":"Reprod. Biomed. Online"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the Risk of Colorectal Cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","article-title":"Statin use and cancer risk in the General Practice Research Database","volume":"90","author":"Kaye","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20758","article-title":"Cancer risk among statin users: A population-based cohort study","volume":"114","author":"Friis","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/archinte.160.15.2363","article-title":"3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer","volume":"160","author":"Blais","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1200\/JCO.2007.10.8936","article-title":"Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients","volume":"25","author":"Bonovas","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10552-013-0326-6","article-title":"Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies","volume":"25","author":"Liu","year":"2013","journal-title":"Cancer Causes Control."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3748\/wjg.v20.i7.1858","article-title":"Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies","volume":"20","author":"Lytras","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/1940-6207.CAPR-11-0113","article-title":"Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies","volume":"4","author":"Lee","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_105","first-page":"5043","article-title":"The role of statins for primary prevention in non-elderly colorectal cancer patients","volume":"34","author":"Sehdev","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2016.02.017","article-title":"Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases","volume":"14","author":"Ananthakrishnan","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.1038\/s41598-019-49877-5","article-title":"Statin use and the risk of colorectal cancer in a population-based electronic health records study","volume":"9","author":"Pontes","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_108","first-page":"255","article-title":"Statins and Colorectal Cancer\u2014A Systematic Review","volume":"128","author":"Dobrzycka","year":"2018","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/cam4.2151","article-title":"Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"djv045","DOI":"10.1093\/jnci\/djv045","article-title":"Statin Use and Survival After Colorectal Cancer: The Importance of Comprehensive Confounder Adjustment","volume":"107","author":"Hoffmeister","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Krens, L.L., Simkens, L.H.J., Baas, J.M., Koomen, E.R., Gelderblom, H., Punt, C.J.A., and Guchelaar, H.-J. (2014). Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112201"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.371","article-title":"A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI\/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer","volume":"113","author":"Lim","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20517\/2394-4722.2018.37","article-title":"Immunotherapy in colorectal cancer treatment: Actual landscape and future perspectives","volume":"4","author":"Bittoni","year":"2018","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_115","unstructured":"GLOBOCAN 2018 Database (2020, August 20). Issued by World Health Organization (WHO). Available online: http:\/\/gco.iarc.fr\/today."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:41Z","timestamp":1760177561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":117,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102724"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102724","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}